261 related articles for article (PubMed ID: 16360544)
1. What is the best schedule for administration of gemcitabine-taxane?
Colomer R
Cancer Treat Rev; 2005; 31 Suppl 4():S23-8. PubMed ID: 16360544
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-taxane experience in the treatment of metastatic breast cancer.
Barnadas A
Cancer Treat Rev; 2005; 31 Suppl 4():S11-5. PubMed ID: 16360542
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Sledge GW
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
Zielinski CC
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):36-40. PubMed ID: 14768404
[TBL] [Abstract][Full Text] [Related]
6. How to maximize the efficacy of taxanes in breast cancer.
Tubiana-Hulin M
Cancer Treat Rev; 2005; 31 Suppl 4():S3-9. PubMed ID: 16360546
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Murad AM
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
[TBL] [Abstract][Full Text] [Related]
8. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
O'Shaughnessy J
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):15-21. PubMed ID: 14768400
[TBL] [Abstract][Full Text] [Related]
10. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
Yardley DA; Burris HA; Hanson S; Greco FA; Spigel DR; Barton J; Hainsworth JD
Clin Breast Cancer; 2009 Aug; 9(3):178-83. PubMed ID: 19661042
[TBL] [Abstract][Full Text] [Related]
11. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
O'Shaughnessy JA; Vukelja S; Marsland T; Kimmel G; Ratnam S; Pippen JE
Clin Breast Cancer; 2004 Jun; 5(2):142-7. PubMed ID: 15245619
[TBL] [Abstract][Full Text] [Related]
14. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Levy C; Fumoleau P
Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and paclitaxel in metastatic breast cancer: a review.
Colomer R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):8-12. PubMed ID: 15685819
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
[TBL] [Abstract][Full Text] [Related]
19. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
Lopez M
Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Fountzilas G; Dafni U; Dimopoulos MA; Koutras A; Skarlos D; Papakostas P; Gogas H; Bafaloukos D; Kalogera-Fountzila A; Samantas E; Briasoulis E; Pectasides D; Maniadakis N; Matsiakou F; Aravantinos G; Papadimitriou C; Karina M; Christodoulou C; Kosmidis P; Kalofonos HP
Breast Cancer Res Treat; 2009 May; 115(1):87-99. PubMed ID: 18483853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
